Radient Pharmaceuticals Corp.
| OTC Markets: RXPC
Radient Pharmaceuticals Corp. engages in the research, development, manufacturing, sale and marketing of its Onko-Sure test kit, a proprietary in-vitro diagnostic cancer test. It markets its Onko-Sure test kits in the United States, Canada, Chile, Europe, India, Korea, Japan, Taiwan, Vietnam and other markets throughout the world. It enables physicians and their patients to detect and/or monitor the treatment/recurrence of solid tumors by measuring the accumulation of specific breakdown products in the blood called Fibrin and Fibrinogen Degradation Products. Onko-Sure is a simple, non-invasive blood test designed to be used for the detection and/or monitoring of cancers, including lung, breast, tongue, stomach, liver, colon, rectal, bladder, brain, hematological, prostate, ovarian, esophageal, cervical, uterine, liver, trophoblastic, thyroid, malignant lymphoma, and pancreatic cancers. The company was founded in 1987 and is headquartered in Tustin, CA.